Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Feb 26, 2015 at 9:25 AM EST

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech…

Lee Jackson | Feb 24, 2015 at 10:05 AM EST

Top UBS Health Care Stocks to Buy for 2015 and Beyond

Bought as a basket, these four companies could offer long-term investors a perfect compliment of stocks covering the health care…

Jon C. Ogg | Feb 24, 2015 at 9:50 AM EST

Steep Discount on Health Care REIT Secondary Offering

Health Care REIT has priced its underwritten public secondary offering of 17 million shares, but some investors may be wondering…

Chris Lange | Feb 23, 2015 at 4:45 PM EST

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

ThinkstockAfter the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings…

Chris Lange | Feb 23, 2015 at 1:35 PM EST

Biocept Breaks Through With Columbia Study

Biocept has announced that its blood-based diagnostic was used to determine hormonal status of metastatic breast cancer patients in a…

Chris Lange | Feb 23, 2015 at 9:15 AM EST

Is Rigel Getting Enough From Bristol-Meyers?

Rigel Pharmaceuticals and Bristol-Myers Squibb announced Monday morning that they have entered into a collaboration agreement.

Lee Jackson | Feb 23, 2015 at 9:05 AM EST

Jefferies 4 Top Pharmaceutical Stocks to Buy

One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks…

Chris Lange | Feb 18, 2015 at 3:31 PM EST

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene has announced that the FDA expanded the existing indication for Revlimid in conjunction with dexamethasone.

Chris Lange | Feb 18, 2015 at 8:50 AM EST

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences has announced that it will have another public offering of its common stock to raise roughly $225 million.

Lee Jackson | Feb 18, 2015 at 8:25 AM EST

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid…

Chris Lange | Feb 17, 2015 at 3:01 PM EST

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.

Chris Lange | Feb 17, 2015 at 10:00 AM EST

The Driving Force Behind Medtronic Earnings

Tuesday before the markets opened, Medtronic (NYSE: MDT) reported better-than-expected fiscal third-quarter financial results.

Trey Thoelcke | Feb 16, 2015 at 11:05 AM EST

What to Expect From Medtronic Earnings

Medical device maker Medtronic is scheduled to report its fiscal third-quarter results Tuesday before the opening bell.

Chris Lange | Feb 11, 2015 at 9:40 AM EST

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech…

Chris Lange | Feb 9, 2015 at 2:43 PM EST

Analyst Sees BioMarin Up Another 25%

BioMarin Pharmaceutical received a favorable analyst call from Merrill Lynch in Monday.

1 … 269 270 271 272 273 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

Top UBS Health Care Stocks to Buy for 2015 and Beyond

Steep Discount on Health Care REIT Secondary Offering

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

Biocept Breaks Through With Columbia Study

Is Rigel Getting Enough From Bristol-Meyers?

Jefferies 4 Top Pharmaceutical Stocks to Buy

Is Revlimid Becoming a Catch-All Cancer Drug?

Neurocrine Biosciences Announces New Offering

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Why 1 Analyst Sees Over 50% Upside in Sarepta

The Driving Force Behind Medtronic Earnings

What to Expect From Medtronic Earnings

Short Sellers Look Scared of Big Biotech

Analyst Sees BioMarin Up Another 25%

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

Top UBS Health Care Stocks to Buy for 2015 and Beyond

Steep Discount on Health Care REIT Secondary Offering

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

Biocept Breaks Through With Columbia Study

Is Rigel Getting Enough From Bristol-Meyers?

Jefferies 4 Top Pharmaceutical Stocks to Buy

Is Revlimid Becoming a Catch-All Cancer Drug?

Neurocrine Biosciences Announces New Offering

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Why 1 Analyst Sees Over 50% Upside in Sarepta

The Driving Force Behind Medtronic Earnings

What to Expect From Medtronic Earnings

Short Sellers Look Scared of Big Biotech

Analyst Sees BioMarin Up Another 25%

After Reviewing Every International Developed Market ETF These 3 Cover Japan and Europe Better Than Anything Else

Emerging Markets Are Delivering Over 22 Percent Returns and Most American Investors Are Missing It Entirely

Why SOXX’s Next 12 Months Hinge on Five Tech Giants’ Capex Decisions

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later